Renal vein thrombosis (RVT) is a rare condition characterized by the formation of a blood clot in one or both of the renal veins. Bilateral involvement is more common, but when the condition affects only one side, it usually occurs on the left due to more extensive venous vasculature compared to the right side. RVT can be caused by various factors such as trauma, dehydration, malignancy, and a hypercoagulable state. Acute RVT is typically more severe than chronic, and it can cause symptoms such as renal infarction, acute kidney injury, renal failure, severe flank pain, and hematuria. Some cases of RVT have also been linked to coronavirus disease 2019 (COVID-19), which is widely recognized to induce a hypercoagulable state. The standard treatment for RVT is warfarin but in this case report, we describe a COVID-19 patient with RVT whose thrombus was successfully treated with direct-acting oral anticoagulant (DOAC) apixaban for six months.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281477PMC
http://dx.doi.org/10.7759/cureus.39296DOI Listing

Publication Analysis

Top Keywords

renal vein
8
vein thrombosis
8
case report
8
hypercoagulable state
8
rvt
6
renal
5
thrombosis treated
4
treated apixaban
4
apixaban patient
4
patient covid-19
4

Similar Publications

Ticagrelor, a reversible platelet P2Y receptor antagonist, exerts various pleiotropic actions, some of which are at least partially mediated through adenosine. We studied the ticagrelor and adenosine effect on the angiogenic properties of progenitor CD34-derived endothelial colony-forming cells (ECFCs). Angiogenesis studies were performed in vitro using capillary-like tube formation and spheroid-based angiogenesis assays.

View Article and Find Full Text PDF

: Vascular access complications, particularly high venous pressure, pose significant challenges for hemodialysis patients undergoing hemodialysis. Limited research has focused on identifying predictive factors for invasive treatment. This study aimed to identify patients who might benefit from frequent monitoring and conservative management based on duplex ultrasound (DUS) evaluation.

View Article and Find Full Text PDF

Background: The pathogenesis of acute kidney injury (AKI) is not fully understood. Tax1-binding protein 1 (TAX1BP1) modulates inflammation and apoptosis through the NF-kB signaling pathway, however, its specific role in ischemic AKI remains unclear.

Methods: We injected a TAX1BP1 overexpression plasmid into the tail vein of male C57BL/6 mice, followed by clamping the bilateral renal arteries to induce AKI.

View Article and Find Full Text PDF

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease worldwide. Despite advancements in various treatments, the prevalence of DKD continues to rise, leading to a significant increase in the demand for dialysis and kidney transplantation. This study aimed to evaluate the effects of a Small cell+Ultra Potent+Scale UP cell (SMUP-Cell), a type of human umbilical cord blood-derived mesenchymal stem cell, on DKD in the db/db mouse model of type 2 diabetes mellitus.

View Article and Find Full Text PDF
Article Synopsis
  • Neutrophil extracellular traps (NETs) contribute to inflammation and worsen tissue damage, being linked to acute rejection in kidney transplants, emphasizing the need for NET regulation in treatment.
  • Researchers analyzed the GSE50058 dataset to identify NET-related biomarkers and developed a diagnostic model using WGCNA and machine learning, while also studying immune cell infiltration in kidney transplant rejection.
  • Four biomarkers were identified: GPX3 (negatively correlated with rejection), B2M, CDK1, and MAP3K5 (positively correlated), and the study validated their diagnostic and clinical use through various analytical methods, revealing their significant association with immune cell infiltration levels.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!